September 15, 2023 News by Andrea Lobo, PhD Benefits of long-term Tysabri seen in RRMS patients in Japan: Study Tysabri (natalizumab) significantly reduced the development of brain lesions on MRI scans in Japanese people with relapsing-remitting multiple sclerosis (RRMS), according to a new study. The therapy also eased or stabilized disability levels in most patients after five years of treatment, and significantly reduced the annual rate of…
July 13, 2022 News by Steve Bryson, PhD For MS Patients in Japan, Kesimpta May Be Best at Preventing Relapses Kesimpta (ofatumumab) may be more effective at reducing relapse rates than other disease-modifying therapies (DMTs) in Japanese adults with relapsing forms of multiple sclerosis (MS), according to a review of clinical trial data. Although the differences were not statistically significant, the study provided comparative evidence that may help…
April 15, 2020 News by Steve Bryson, PhD Gray Matter Lesions Affect Cognition in Japanese MS Patients as Well, Study Says People in Japan with lesions in the cerebral cortex due toĀ multiple sclerosis (MS) were found to have greater cognitive problems, or difficulties thinking, than those without lesions in this area of mostly gray matter that surrounds the brain, a study reports.Ā Lesions confined to the…
August 8, 2019 News by Jose Marques Lopes, PhD Specific Mutation and Amino Acid Change Linked to MS Risk in Study from Japan An amino acid change to phenylalanine, and a specific class I HLA gene variant are associated with greater risk forĀ multiple sclerosis (MS), according to a study in Japanese patients. Researchers also identified an HLA variant, or mutation, associated with neuromyelitis optica spectrum disorder (NMOSD), an autoimmune condition…
February 2, 2017 News by admin Long-term Treatment with Gilenya Found to Limit Lesions, Relapses in Japanese MS Patients Continuous treatment with Gilenya (fingolimod)Ā helps limit relapses and detectable lesions in multiple sclerosis (MS) patients, according to a three-year, follow-upĀ studyĀ in Japan. The results confirmĀ the findings of trials conducted in predominantly Caucasian populations. The findings were reported in the study, āLong-term efficacy and safety of fingolimod in…
May 24, 2016 News by InĆŖs Martins, PhD New Research Center at UC San Diego to Focus on Microbiome and Immunology TheĀ University of California (UC) San Diego School of Medicine and Chiba University School of Medicine, Japan, are working togetherĀ to establishĀ a newĀ center forĀ immunology research, with a particular focusĀ on the microbiome and mucosal immune responses that are knownĀ to play a crucial role in a variety of diseases, including multiple sclerosis (MS). āThis…
December 7, 2015 News by Patricia Silva, PhD Relapsing Multiple Sclerosis Treatment Now Available in Japan Takeda Pharmaceutical, a pharmaceutical company based in Osaka, Japan, recently announcedĀ that a widely approved drug treatment forĀ the prevention of relapses in multiple sclerosis (MS)Ā is nowĀ available in Japan as well. Copaxone,Ā (glatiramer acetate; 20 mg daily subcutaneous injection), developed by Teva Pharmaceuticals, is an immunomodulatory drug designed toĀ act as…
September 30, 2015 News by Patricia Silva, PhD Teva’s COPAXONE Approved in Japan for the Prevention of Relapse Remitting Multiple Sclerosis Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions, recently announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the once per day 20 mg injection of COPAXONEĀ®Ā as prophylaxis for relapses in multiple sclerosis (MS). Glatiramer acetate, the active…
September 15, 2015 News by Patricia Silva, PhD Gut Microbiota Imbalance Discovered in Multiple Sclerosis Patients A new study recently published in the journal PLOS One revealed that multiple sclerosis (MS) patients have a microbial imbalance (dysbiosis) in their gut microbiota that is most likely linked to the disease pathogenesis. The study is entitled āDysbiosis in the Gut Microbiota of…